ClearPoint Neuro Reports Second Quarter 2026 Results
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro Reports First Quarter 2026 Results
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
ClearPoint Neuro Completes Acquisition of IRRAS
ClearPoint Neuro Reports Third Quarter 2025 Results
ClearPoint Neuro Announces Agreement to Acquire IRRAS
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer